Gilead to present late breaking data at The Liver Meeting 2023

Gilead Sciences announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting, from November 10-14. Key findings from more than 80 presentations will include a late-breaker oral presentation of primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex, an investigational therapy in the U.S. and outside of the European Economic Area, in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta virus, and an integrated analysis of Week 96 data from pivotal Phase 2b and Phase 3 studies evaluating the efficacy and safety of bulevirtide monotherapy. Gilead will also present long-term results from ongoing studies of Vemlidy in chronic hepatitis B, two-year efficacy, safety, and resistance data on TAF in pediatric patients with chronic HBV. In the U.S., Vemlidy is indicated for the treatment of chronic HBV in adults and pediatric patients 12 years of age and older with compensated liver disease. The use of Vemlidy for other patient populations is investigational, and the safety and efficacy for these uses have not been established. “We look forward to sharing our latest findings in the treatment of people living with HDV with the broader liver community at The Liver Meeting,” said Anu Osinusi, Vice President Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead Sciences. “Despite meaningful advances in the treatment of people living with viral hepatitis, much work remains to improve diagnosis, care, and services to address the unmet needs of people living with viral hepatitis and pursue our continued commitment to help achieve HBV and HCV elimination goals by 2030.”